Ascidian Interim President & CEO Mike Ehlers explains the scientific concept of RNA exon editing

Salim Syed discusses this morning’s FOREST-HCM update, Gilead’s Trodelvy news, CRISPR’s allo CAR-T pivot, and more.

Jeremy Levin walks us through the science of Ovid's CNS-focused pipeline, gives his take on the health of the biotech.

Tim Opler discusses the M&A environment, IPO windown, PIPE and crossover financings, and more.

Matt Gline reflects on learnings from the Telavant success, and why he thinks Immunovant's FcRn might be best in class.

Cantor Fitzgerald biotech analyst Eric Schmidt talks about themes he thinks will work in 2024, tracking important launches, and technologies

Herriot Tabuteau on his company's recent launches, submissions migraine and fibromyalgia, key data in narcolepsy and Alzheimer's, and more.

Head of Healthcare & Life Sciences Capital Markets Johanna Grossman describes the assets that NYSE has available for biotech companies that

ChemoMetec's VP of Operations Jonas la Cour walks us through his company's NucleoCounter technology.

LumaCyte SVP Colin Hebert walks us through the company's Radiance platform instrument.

Lonza Sales Manager Jerry Jiang walks us through the company's automated cell therapy manufacturing platform.

Jeff Galvin explains how previous attempts at modifying CCR5 in T-cells have taught us to more precisely target HIV and from addition angles

Thermo Fisher Scientific Senior Manager Russell Jerres walks us through the DynaCellect, Rotea, and Xenon systems.

Brent Saunders discusses the launch of MEIBO and XIIDRA, talks about priorities for 2024, and gives the latest on BeautyHealth and Roam.

Michael Yee shares takeaways from last week's conference in San Francisco and highlights his top names to watch.

Trevor Martin describes how Mammoth is working on the evolution of CRISPR to help make it more versatile for potential use in broad in-vivo.

Chris Gibson describes the new technologies that are accelerating and refining drug development.

George Simeon explains how the 876-participant study showed non-inferiority vs Shingrix and lower rates of solicited local and SAEs.

Vipin Garg explains the theory of how GLP-1 cause weight loss and gives the rationale for adding glucagon agonism for added effect.

Harvey Berger describes the science of ferroptosis and his experience working with Kojin's scientific founder Stuart Schreiber.